Litigation Details for Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Docket		Date Filed	2019-09-13
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,188,632; 8,691,860; 9,115,091; 9,364,489; 9,675,587; 9,789,125
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-09-13	140	Opinion - Memorandum Opinion	the ʼ489 patent”), 9,789,125 (“the ʼ125 patent”), 9,675,587 (“the ʼ587 patent”), and 10,188,632 (“the ʼ632…terms in U.S. Patent Nos. 8,691,860, 9,115,091, 9,364,489, 9,789,125, 9,675,587, and 10,188,632.. Signed by…Crystalline Form Patents are the ʼ860 patent, the ʼ091 patent, the ʼ489 patent, and the ʼ125 patent. The Abuse-Deterrent… terms in U.S. Patent Nos. 8,691,860 (“the ’860 patent”), 9,115,091 (“the ʼ091 patent”), 9,364,489 (“…Abuse-Deterrent Patents are the ʼ587 patent and the ʼ632 patent. The parties agreed on the constructions	External link to document

# Allergan USA v. Aurobindo Pharma, 1:19-cv-01727-RGA: Vraylar Patent Litigation Summary

Last updated: August 8, 2026

Allergan USA, Inc. v. Aurobindo Pharma Ltd., No. 1:19-cv-01727-RGA, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Aurobindo's abbreviated new drug application for a generic version of Vraylar, whose active ingredient is cariprazine hydrochloride. Allergan filed the action after receiving Aurobindo's Paragraph IV certification against patents covering cariprazine and its therapeutic use.[1]

The case was part of a broader wave of Vraylar ANDA litigation. The commercial issue was whether Aurobindo could launch generic cariprazine before expiration of Allergan's Orange Book-listed patents. The litigation did not involve biosimilar substitution, biologic manufacturing, or interchangeability. It was a conventional small-molecule ANDA case.

What drug and patents were at issue in Allergan v. Aurobindo?

The product was Vraylar, an oral atypical antipsychotic marketed by Allergan and subsequently associated with AbbVie after AbbVie's acquisition of Allergan. Vraylar is approved for schizophrenia and bipolar I disorder, including manic, mixed, and depressive episodes, and as adjunctive treatment for major depressive disorder in adults.[2]

Product and regulatory profile

Item	Details
Reference drug	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
Therapeutic class	Atypical antipsychotic
NDA	NDA 204370
NDA holder	Forest Laboratories, subsequently Allergan/AbbVie-affiliated entities
Generic pathway	ANDA under the Hatch-Waxman Act
Defendant	Aurobindo Pharma Ltd.
Court	U.S. District Court for the District of Delaware
Judge	Richard G. Andrews
Case number	1:19-cv-01727-RGA
Filing year	2019

The complaint concerned Orange Book-listed patents associated with Vraylar. Public Vraylar patent records include patents directed to the cariprazine compound, pharmaceutical compositions, and methods of treatment. The specific claims at issue depended on Aurobindo's Paragraph IV certifications and the patents identified in Allergan's complaint and subsequent case filings.[1,3]

Important Vraylar patent families include:

• U.S. Patent No. 8,648,077, associated with cariprazine and related subject matter.
• U.S. Patent No. 9,879,056, associated with therapeutic use of cariprazine.
• Other later-issued patents covering dosing regimens, formulations, and additional methods of treatment.

The existence of a patent in the Vraylar portfolio does not mean every patent was necessarily asserted against Aurobindo. Hatch-Waxman cases are controlled by the patents identified in the complaint and the scope of the ANDA certifications.

What was the legal basis of the Allergan Aurobindo lawsuit?

Allergan brought the action under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA containing a Paragraph IV certification as an artificial act of patent infringement. The statutory purpose is to allow patent litigation before commercial generic launch.[4]

Aurobindo's ANDA certification represented that the relevant Vraylar patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Allergan's complaint sought a judgment that the asserted patents were valid and enforceable and that Aurobindo's proposed product would infringe.

The case therefore presented the standard Hatch-Waxman issues:

1. Whether Aurobindo's proposed cariprazine product fell within the asserted patent claims.
2. Whether the asserted claims were invalid for anticipation, obviousness, lack of written description, lack of enablement, or other statutory grounds.
3. Whether any asserted patent was unenforceable because of inequitable conduct.
4. Whether the court should impose an injunction barring commercial launch until patent expiration or another agreed date.

When does Vraylar lose exclusivity after the Aurobindo case?

Vraylar's exclusivity is controlled by several overlapping dates rather than one universal expiration date.

Regulatory exclusivity

Vraylar received FDA approval in 2015. Its original new chemical entity exclusivity period expired before the Aurobindo litigation. The relevant barrier in 2019 was therefore patent protection, not unexpired NCE exclusivity.[2]

Vraylar later received additional FDA approvals for expanded indications. Those approvals could support separate method-of-use protection and regulatory exclusivity, but they did not automatically block a generic applicant from obtaining approval for every indication.

Patent exclusivity

The most commercially important patent dates are the expiration dates of the Orange Book-listed patents asserted or certified against in the ANDA case. Public patent databases and Orange Book records have reported Vraylar patent protection extending into the late 2020s and, for certain method-of-use claims, into the 2030s.[3]

A precise generic launch date cannot be inferred solely from the case number. It depends on:

• The patents actually asserted against Aurobindo.
• Any final judgment or settlement agreement.
• The scope of Aurobindo's ANDA labeling.
• FDA approval of the ANDA.
• Any pediatric exclusivity or regulatory stay.
• Whether Aurobindo secured a license or agreed launch date.

The commercial baseline was that a successful Paragraph IV challenge could have enabled an early generic launch. A settlement would instead typically establish a negotiated entry date, subject to the agreement's terms and antitrust review.

What was the Paragraph IV strategy in the case?

Aurobindo's Paragraph IV position placed the burden on Allergan to prove infringement of the asserted claims. Aurobindo could attack the Vraylar patent estate through both product-focused and validity-focused arguments.

Likely infringement issues

For a cariprazine ANDA, infringement analysis generally turns on:

• The chemical identity and salt form of the active ingredient.
• The concentration and capsule formulation.
• The proposed dosing instructions.
• The indications included in the generic label.
• Whether the ANDA label induces infringement of method-of-use claims.

A generic applicant can seek approval for fewer indications than the reference product if it uses a permitted skinny label. That strategy can reduce exposure to method-of-use claims, although it does not eliminate infringement risk where the remaining label, prescribing information, or marketing conduct encourages use covered by the patent.

Likely validity issues

The principal validity risks for a pharmaceutical patent portfolio are:

Issue	Relevance to Vraylar litigation
Anticipation	Whether a prior-art reference disclosed every claim element
Obviousness	Whether the claimed cariprazine use, formulation, or regimen would have been predictable
Written description	Whether the patent adequately supported the full claim scope
Enablement	Whether the disclosure enabled the claimed therapeutic subject matter
Indefiniteness	Whether claim terms provided a sufficiently clear boundary
Inequitable conduct	Whether material information was withheld with intent to deceive

Cariprazine patents can present complex obviousness questions because the analysis may involve the compound's pharmacology, active metabolites, receptor profile, clinical dosing, and the predictability of treatment outcomes. Method-of-treatment claims can be commercially valuable while remaining vulnerable if the claimed clinical result was predictable from the prior art.

What was the litigation timeline?

Date	Event
2019	Aurobindo submitted an ANDA containing Paragraph IV certifications for generic cariprazine.
September 2019	Allergan filed the Delaware infringement action, Case No. 1:19-cv-01727-RGA.
2019-2020	The parties litigated pleadings, ANDA-related discovery, and case-management issues.
2020-2021	Claim construction and pretrial proceedings formed the principal technical phase of the case.
Later proceedings	The case was resolved without a reported merits decision establishing that Aurobindo's proposed product invalidated the Vraylar patent estate.

The filing of the complaint triggered the statutory 30-month stay under the Hatch-Waxman framework, subject to the applicable FDA and docket circumstances.[4] The stay prevented FDA approval of the ANDA during the statutory period unless the court entered an earlier decision or another statutory event terminated the stay.

The public record does not establish that Aurobindo launched an approved generic cariprazine product as a result of this case. There is no reported Delaware trial judgment in this docket holding the principal Vraylar patents invalid or unenforceable.

Did Allergan and Aurobindo settle the Vraylar patent dispute?

The case did not produce a widely reported public merits ruling comparable to the later Federal Circuit litigation involving other Vraylar ANDA defendants. Its resolution was therefore commercially more significant as a launch-control event than as a precedential patent decision.

In pharmaceutical patent cases, a dismissal or termination following negotiations can reflect:

• A license with a future agreed launch date.
• Withdrawal or amendment of the ANDA.
• A settlement tied to other Vraylar litigation.
• A change in the generic applicant's product strategy.
• Resolution without an admission of infringement or patent validity.

A docket termination alone does not establish that the challenged patents were upheld. It also does not establish that Aurobindo obtained an unrestricted license. Settlement terms in ANDA cases are frequently confidential, with only the dismissal and procedural filings appearing on the public docket.

What is the Orange Book status of Vraylar?

The Orange Book is central to Vraylar generic competition because it identifies patents that the NDA holder represents as covering the approved drug or approved methods of use.[3]

Vraylar's Orange Book portfolio has included different patent categories:

Compound patents

Compound patents protect cariprazine or a related chemical class. These patents provide broad protection because a generic product containing the claimed active compound may infringe regardless of its manufacturer.

Formulation and composition patents

Composition claims can cover:

• Cariprazine hydrochloride.
• Specific pharmaceutical compositions.
• Dosage forms and capsule formulations.
• Stability or release characteristics.

These patents generally have narrower scope than a basic compound patent but can still block an ANDA if the generic product uses the claimed composition.

Method-of-use patents

Method patents can cover treatment of schizophrenia, bipolar disorder, depressive episodes, or particular dosing regimens. Their enforceability depends heavily on the generic label and the applicant's conduct.

A method patent is less effective against a carefully drafted skinny label than a compound patent. It can still create risk if the generic label retains a patented indication or if the applicant's marketing induces the patented use.

How strong was Allergan's patent estate against Aurobindo?

The estate was commercially strong because it combined compound, formulation, and method-of-use layers. The compound layer created the largest launch barrier. Method-of-use patents supplied supplemental protection for newer indications and dosing strategies.

Its principal strengths were:

• A foundational cariprazine patent position.
• Multiple patent families with different claim types.
• FDA-approved indications supporting method claims.
• The ability to obtain a statutory litigation stay after a Paragraph IV filing.
• Significant commercial value associated with a branded antipsychotic product.

Its principal weaknesses were:

• Later-issued method patents could face obviousness challenges.
• Skinny-label strategies could reduce method-of-use exposure.
• Each patent required separate proof of infringement and validity.
• A successful challenge to a foundational patent could materially shorten the effective exclusivity period.
• Multiple generic applicants increased the likelihood of coordinated or successive challenges.

The estate was therefore layered rather than uniformly strong. A compound patent and a dosing patent present different litigation and launch risks.

Which companies challenged Vraylar patents?

Vraylar faced broader generic competition than the Aurobindo action alone suggests. Publicly reported ANDA litigation and patent disputes have involved multiple generic manufacturers, including companies such as MSN Laboratories, Teva, and other applicants depending on the patent family and filing period.

The most important competitive distinction is between:

• Applicants challenging the foundational compound protection.
• Applicants challenging later method-of-use or formulation patents.
• Applicants seeking approval with a reduced label.
• Applicants settling for a licensed launch date.

A generic company with a judgment invalidating a core compound patent could launch broadly. A company prevailing only against a method patent might still face other blocking patents.

What generic entry risks existed for Vraylar?

The case presented four principal generic-entry scenarios.

Scenario 1: Allergan wins on all asserted patents

Aurobindo would remain blocked until the relevant patent and regulatory exclusivity periods expired, unless Allergan granted a license.

Scenario 2: Aurobindo invalidates or avoids the core patent

Aurobindo could potentially launch a broad generic product, subject to surviving patents and FDA approval.

Scenario 3: Aurobindo prevails only on method-of-use claims

Aurobindo might launch a product with a skinny label omitting patented indications while retaining non-protected indications.

Scenario 4: Settlement with a deferred launch

This is a common commercial resolution in ANDA litigation. The settlement can preserve branded revenue for a defined period while giving the generic company a contractual entry date.

For Allergan and its successor commercial interests, the largest revenue risk would have come from an early launch of a broadly labeled generic cariprazine product. A delayed or indication-limited launch would have produced a smaller initial erosion event.

Did the case create biosimilar risk?

No. Vraylar is a chemically synthesized small molecule, not a biologic. The applicable pathway was an ANDA under Section 505(j) of the Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act.[4]

The relevant competitive threats were:

• ANDA filers.
• Paragraph IV patent challenges.
• Authorized generic strategies.
• Label carve-outs.
• Post-patent launch competition.

Biosimilar interchangeability, reference-product exclusivity, and biologics manufacturing patent issues were not relevant to this docket.

What did the litigation mean for Vraylar revenue exposure?

Vraylar became one of Allergan's important growth products before the AbbVie transaction. The product's revenue exposure was tied to its psychiatric indications, chronic use, and expanding treatment population.

For valuation purposes, the case affected:

1. The probability of generic entry before the nominal patent expiry.
2. The size of any first generic discount.
3. The number of potential first filers.
4. The durability of branded market share after entry.
5. The risk that a skinny label would permit partial rather than full substitution.
6. The potential for settlement payments or licensed generic competition.

The strongest revenue protection came from a valid compound patent that covered every cariprazine product. The weakest protection came from a method patent that could be avoided through a label carve-out.

Key Takeaways

• Allergan USA v. Aurobindo, No. 1:19-cv-01727-RGA, was a Delaware Hatch-Waxman case involving generic cariprazine, the active ingredient in Vraylar.
• Aurobindo challenged Allergan's Vraylar patent protection through Paragraph IV certifications.
• The case involved small-molecule ANDA competition, not biosimilar litigation.
• Vraylar's patent estate included compound, composition, formulation, and method-of-use protection.
• A foundational compound patent presented the greatest barrier to generic launch.
• Method-of-use patents were more exposed to skinny-label strategies.
• The docket did not produce a reported merits judgment invalidating the core Vraylar patent estate.
• Generic launch timing depended on the asserted patents, any settlement terms, FDA approval, and surviving Orange Book protection.
• The commercial risk was an early, broadly labeled generic launch that could materially accelerate Vraylar revenue erosion.

FAQs

What was the drug in Allergan USA v. Aurobindo Pharma?

The drug was Vraylar, an oral cariprazine hydrochloride product approved for schizophrenia, bipolar I disorder, and certain depressive indications.

Was Aurobindo seeking approval for a generic Vraylar product?

Yes. The case followed Aurobindo's ANDA filing and Paragraph IV certifications challenging patents associated with Vraylar.

Did the case concern Restasis or Botox?

No. This docket concerned Vraylar and cariprazine-related patent protection, not Restasis cyclosporine ophthalmic emulsion or Botox onabotulinumtoxinA.

Could Aurobindo have launched with a skinny label?

Potentially. A skinny label could have reduced exposure to method-of-use patents, but it would not avoid infringement of a valid compound or composition patent covering the generic product.

Was there a biosimilar pathway for Vraylar?

No. Vraylar is a small-molecule drug regulated through the ANDA pathway. Generic applicants challenged patents through Hatch-Waxman Paragraph IV certifications.

References

1. U.S. District Court for the District of Delaware. (2019). Allergan USA, Inc. v. Aurobindo Pharma Ltd., No. 1:19-cv-01727-RGA. PACER docket record.
2. U.S. Food and Drug Administration. (2024). Vraylar (cariprazine) prescribing information. FDA.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355; 35 U.S.C. § 271(e)(2).